V3-specific neutralizing antibodies in sera from HIV-1 gp160-immunized volunteers block virus fusion and act synergistically with human monoclonal antibody to the conformation-dependent CD4 binding site of gp120. NIH-NIAID AIDS Vaccine Clinical Trials Network.

Sera from 11 volunteers immunized with a recombinant HIV-1 gp160-expressing vaccinia virus (HIVAC-1e; Oncogen/Bristol-Myers Squibb, Seattle, WA) and boosted with baculovirus-derived rgp160 (VaxSyn; MicroGeneSys, Inc., Meriden, CT) were evaluated for functional serum antibodies and their epitopes. Se...

Full beskrivning

Sparad:
Bibliografiska uppgifter
Huvudupphovsmän: Montefiori, D C, Graham, B S, Zhou, J, Bucco, R A, Schwartz, D H, Cavacini, L A, Posner, M R
Materialtyp: Artigo
Språk:Inglês
Publicerad: 1993
Ämnen:
Research Article
Länkar:https://ncbi.nlm.nih.gov/pmc/articles/PMC294922/
https://ncbi.nlm.nih.gov/pubmed/8349820
Taggar: Lägg till en tagg
Inga taggar, Lägg till första taggen!

Liknande verk